Internal Medicine, Hematology & Oncology · Seattle, WA
NPI
1043269392
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1100 9th Ave
Seattle, WA, 98101
Phone (206) 223-6600
Groups this clinician bills Medicare through
Medicare paid, 2024
$127K
3,145 services
Medicare patients, 2024
445
Average age 75
Drug cost, 2024
$9.8M
4,581 prescriptions
Company payments, 2025
$2,412
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David M Aboulafia was code 99214 (office e&m - established), 510 times for 243 patients. In total David M Aboulafia billed 3,145 services in 27 codes, and Medicare paid $127K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-06-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 510 | 243 | $73.94 | $38K |
| 36415 Venipuncture Blood Collection | Office | 416 | 176 | $8.61 | $3,583 |
| 99214 Office E&M - Established | Office | 386 | 187 | $98.66 | $38K |
| 99233 Hospital E&M - Subsequent | Facility | 153 | 36 | $99.14 | $15K |
| 99215 Office E&M - Established | Facility | 68 | 45 | $113.22 | $7,699 |
| 99215 Office E&M - Established | Office | 37 | 26 | $153.12 | $5,665 |
| 99223 Hospital E&M - Initial | Facility | 32 | 26 | $144.84 | $4,635 |
| 99232 Hospital E&M - Subsequent | Facility | 31 | 19 | $65.52 | $2,031 |
| 99205 Office E&M - New | Facility | 27 | 27 | $139.99 | $3,780 |
| 99222 Hospital E&M - Initial | Facility | 22 | 20 | $108.84 | $2,394 |
| 81003 Clinical Chemistry | Office | 18 | 14 | $2.20 | $39.6 |
| 99211 Office E&M - Established | Office | 15 | 14 | $20.85 | $313 |
By year: 2022 $150K for 6,324 services; 2023 $151K for 5,452 services; 2024 $127K for 3,145 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 416 | 176 | $8.61 | $3,583 |
| 81003 Clinical Chemistry | 18 | 14 | $2.20 | $39.6 |
Medicare prescription drug claims, 2024
In 2024, the drug David M Aboulafia prescribed most often to Medicare patients was Juluca (Dolutegravir/Rilpivirine), with 223 prescriptions and refills. In total David M Aboulafia wrote 4,581 Medicare prescriptions that cost $9.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Juluca Dolutegravir/Rilpivirine | 223 | 229 | 23 | $816K |
| Atorvastatin Calcium Generic | 216 | 337 | 41 | $1,384 |
| Hydroxyurea Generic | 162 | 329 | 34 | $4,370 |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 150 | 168 | 17 | $619K |
| Gabapentin Generic | 144 | 200 | 23 | $2,079 |
| Descovy Emtricitabine/Tenofov Alafenam | 132 | 137 | 14 | $285K |
| Evotaz Atazanavir Sulfate/Cobicistat | 124 | 135 | 13 | $222K |
| Acyclovir Generic | 103 | 171 | 18 | $914 |
| Levothyroxine Sodium Generic | 98 | 203 | 20 | $1,396 |
| Eliquis Apixaban | 92 | 172 | 23 | $99K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 88 | 102 | Under 11 | $413K |
| Xarelto Rivaroxaban | 86 | 163 | 17 | $89K |
| Tivicay Dolutegravir Sodium | 76 | 76 | Under 11 | $177K |
| Oxycodone Hcl Generic | 60 | 60 | Under 11 | $577 |
| Trazodone Hcl Generic | 58 | 66 | Under 11 | $304 |
Brand drugs: 1,682 claims; generic drugs: 2,885 claims; opioid claims: 186.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David M Aboulafia $2,412 ($2,412 in general payments such as food, travel and fees) from 4 companies. The largest payer was Genmab U.S., Inc. with $2,228.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.